The identification of the candidate genes for autism through linkage and association studies has proven to be a difficult enterprise. An alternative approach is the analysis of cytogenetic abnormalities associated with autism. We present a review of all studies to date that relate patients with cytogenetic abnormalities to the autism phenotype. A literature survey of the Medline and Pubmed databases was performed, using multiple keyword searches. Additional searches through cited references and abstracts from the major genetic conferences from 2000 onwards completed the search. The quality of the phenotype (i.e. of the autism spectrum diagnosis) was rated for each included case. Available specific probe and marker information was used to define optimally the boundaries of the cytogenetic abnormalities. In case of recurrent deletions or duplications on chromosome 15 and 22, the positions of the low copy repeats that are thought to mediate these rearrangements were used to define the most likely boundaries of the implicated 'Cytogenetic Regions Of Interest' (CROIs). If no molecular data were available, the sequence position of the relevant chromosome bands was used to obtain the approximate molecular boundaries of the CROI. The findings of the current review indicate: (1) several regions of overlap between CROIs and known loci of significant linkage and/or association findings, and (2) additional regions of overlap among multiple CROIs at the same locus. Whereas the first finding confirms previous linkage/association findings, the latter may represent novel, not previously identified regions containing genes that contribute to autism. This analysis not only has confirmed the presence of several known autism risk regions but has also revealed additional previously unidentified loci, including 2q37, 5p15,
Introduction
Autism is a neurodevelopmental disorder, which manifests itself in early childhood. It is characterized by impairments in social interaction, communication and the presence of restrictive or stereotyped patterns of behavior. Autism is the core syndrome of the pervasive developmental disorders as described in the fourth edition of the Diagnostic and Statistical Manual (DSM-IV), 1 which also includes other autistic-like disorders.
Prevalence estimates of autism in the general population have gradually increased over the last 20 years. [2] [3] [4] [5] Currently, the prevalence of all the pervasive developmental disorders is estimated to be 27.5/ 10 000. 3 Cumulative evidence from family and twin studies suggests that genetic factors play an important role in the etiology of autism. 6, 7 The prevalence of autism in siblings of autistic children is estimated to be 2-8%, which is much higher than can be expected on the basis of the prevalence in the normal population. 2, [6] [7] [8] Moreover, the concordance of autism in monozygotic twins is approximately 60-91%. 9, 10 The susceptibility for autism is estimated to be more than 90% genetic, and several genes are thought to contribute to the disorder, although the mode of inheritance is unknown. 11 Apart from genetic factors, environmental factors may be involved. Viral infections during or after pregnancy have been associated with autism in some infants, typically with viruses such as rubella, 12 Hemophilus influenzae and cytomegalovirus. 13 Measles, mumps, and rubella vaccination also has been related to autism, 14 but no evidence for this relationship has been found in several other studies. [15] [16] [17] Furthermore, it has been suggested that the mercury-based preservatives of vaccines increase the risk for autism, but this hypothesis has met criticism. 18 Intrauterine exposure to teratogenic drugs including thalidomide and valproate may increase the risk for autism. 19, 20 In addition, obstetric complications have been evoked as risk factor for autism, 21 although a causal relationship has not been demonstrated. 22, 23 Genetic studies have shown linkage between autism and markers located in regions on several chromosomes. However, applying a threshold of 2.2 or 3.6 for the multipoint logarithm of the odds score (MLS), the proposed thresholds for suggestive and significant findings, respectively, 24 only few studies met these thresholds. Based on these studies, regions that may contain genes contributing to autism include 2q, 25 3q, 26 7q 25 (significant linkage), and 11p, 17q 43 and FOXP2 (7q31). 44 For an overview of significant (Po0.05) association studies see Table 2 .
Although of great interest, the data from linkage studies do not directly indicate the gene(s) of interest, and candidate gene studies suffer from methodological difficulties. For example, the a priori selection of candidate genes is difficult, partly because one-third of all human genes is expressed in the brain, or during brain development. 45 Further, consensus on an appropriate level of statistical correction for association tests is difficult to establish. 46 In conclusion, despite the promising results of linkage and association studies, the detection of specific genes contributing to autism has thus far been elusive. This may be due to several problems. Genetic heterogeneity of the autism phenotype, but also the likely possibility of the involvement of several interacting genes and variability in the expression of risk genes 6, 7 are examples of such problems. Also, various epigenetic mechanisms, such as parental imprinting and skewed X-inactivation, may affect the susceptibility for autism. 6 Another complicating factor is the fact that the expression of some genes is influenced by specific regulatory regions that may act from relatively large distances, even from other chromosomes, 47 which further complicates the selection of candidate genes.
An alternative and potentially fruitful approach is the analysis of cytogenetic abnormalities that have been identified in patients with autism. It is estimated that a chromosome abnormality, such as a deletion, duplication, inversion, or translocation, can be identified in about 3% of these patients, 48 and a vast number of such cases have been described in the literature. Several reviews evaluating cytogenetic abnormalities cooccurring with autism have been published. [49] [50] [51] [52] These cytogenetic abnormalities can lead to functional genetic changes in several ways: (1) Dosage effects can occur in some genes as a consequence of changes in gene copy number (e.g. in a deletion or duplication). (2) Breakpoints associated with a rearrangement event may directly disrupt a gene. (3) Genes may be separated from gene-regulatory sequences as a consequence of the rearrangement (position effect). (4) Deletions may lead to the unmasking of a point mutation in a gene located in the corresponding region of the nondeleted homologous chromosome. Our review has four aims. First, to provide an updated list of relevant publications till January 2005. Second, to provide accurate molecular positions of all relevant cytogenetic regions derived upon crosslinking of all available probe and/or banding information from the casereports with the recently nearly completed sequence database of the human genome. The definition of these 'Cytogenetic Regions Of Interest' (CROIs) combined with data regarding expression and functions of the genes contained within these regions may greatly aid in the identification of candidate genes for autism. Third, to present two types of overlap in the findings, namely the overlap between CROIs and loci derived from previous linkage and association studies, and alternatively, overlap among multiple CROIs at the same locus. The significance of the first is mainly a confirmation of previous findings through a different genetic approach. The importance of the latter is the potential identification of novel genomic regions not previously detected by the classic genetic approaches. The fourth aim of the current review is to provide a systematically evaluated rating of the validity of the phenotype (i.e. the clinical diagnosis of autism) of each included case report. This rating adds to the presented data in that it allows for a systematic ranking of CROIs based on the validity of the clinical diagnosis of autism.
Methods
A literature survey of the Medline, and Pubmed databases was performed, using multiple keyword searches with terms such as: 'autis*', 'genetic*', 'cytogenetic*', and 'chromosom*' in several combinations. Additional searches through cited references and abstracts from the major genetic conferences from 2000 onwards (the annual meetings of the American Society of Human Genetics and European Society of Human Genetics) completed the search. All casereports were investigated and summarized, with a special emphasis on the definition of the cytogenetic abnormality and the quality of the phenotype.
The quality of the phenotype (i.e. of the autism spectrum diagnosis) was rated for each included case. Ratings were based on the clinical description, the presence of a psychiatric diagnosis, preferably based on a classification system (e.g. Diagnostic and Statistical Manual of Mental Disorders, International Classification and Diagnostic systems), and the use of standard diagnostic research instruments, such as the Autism Diagnostic Interview-Revised (ADI-R), 53 the Childhood Autism Rating Scale (CARS), 54 and the Autism Diagnostic Observation Schedule-Generic (ADOS-G). 55 The ratings were scored in several consensus meetings of psychiatrists and child psychiatrists (see Table 3 ).
Cases involving chromosomal mosaicism were excluded. Cases with a gene mutation as the most likely genetic cause for autism were excluded as well, for example, patients with fragile-X syndrome caused by FMR1 mutations. All karyotype descriptions are presented according to the International System for human Cytogenetic Nomenclature 1995 (ISCN 1995).
Cases were scrutinized for specific probe/marker information to define optimally the boundaries of the cytogenetic abnormalities. In case of recurrent deletions or duplications on chromosome 15 and 22, the positions of the low copy repeats that are thought to mediate these rearrangements were used to define the most likely boundaries of the CROIs. Positions of the low copy repeats were defined based on the available literature. [56] [57] [58] [59] Several genome databases were used Bars with the same color next to each other indicate the same CROI reported in more than one case report, and thicker bars represent more than two cases in the same case report. Red boxes indicate potential novel regions where more than four case reports overlap at the same locus, without previous linkage and/or association findings. Detailed information on the boundaries of the CROIs, as well as a systematic rating of the phenotype quality is provided in a Supplementary Table online.
Identification of novel autism candidate regions
JAS Vorstman et al (see Table 4 ). If molecular cytogenetic information was lacking, the CROIs could only be defined based on the karyotype descriptions. In such cases, the sequence position of the relevant chromosome bands were used to obtain the approximate molecular boundaries of the CROI. In several cases, marker positions appeared inconsistent with the initial karyotype provided. In those cases, karyotypes were corrected according to the marker information. Finally, in some cases authors were contacted in an attempt to obtain more updated information (for instance, on marker results or methods used to obtain the autism spectrum diagnosis).
Results
The findings from the cytogenetic cases and the data from linkage and association studies are integrated in Figure 1 . This figure is a largely condensed visualization of the overview. The complete graphic overview can be found at the repository WebPages of Molecular Psychiatry. In this diagram all CROIs are represented to scale on each chromosome, along with their sequence coordinates, the phenotype validity ratings, additional comments, and references. Overlap between several CROIs and loci from linkage and association studies are found among others on multiple locations on chromosome 7, on 15q11-q13, and 5p14.
Possible novel regions are indicated by overlap between multiple CROIs without linkage or association findings at the same locus. Such regions are found on 2q37, 5p15, 11q25, 16q22.3, 17p11.2, 18q21.1, 18q23, 22q11.2, 22q13.3 and Xp22.2-p22.3 (red boxes, Figure 1 ).
Discussion
This review is intended to provide researchers in the field of autism with an overview of potentially interesting regions for positional candidate genes. Cytogenetic abnormalities related to autism are provided with well-defined positions of these regions on the corresponding chromosomes whenever possible, and we also included a critical evaluation of the diagnosis of autism in all cases. The results of this literature survey confirm several known loci and indicate several novel CROIs associated with the autism phenotype (see Figure 1 and the repository WebPages of Molecular Psychiatry).
The CROIs are not equally distributed across the human genome, but rather tend to cluster on specific regions. These regions include: chromosome 2 band q37, chromosome 5 band p14-p15, several locations on the long arm of chromosome 7, chromosome 15 band q11-q13, chromosome 11 band q25, chromosome 16 band q22.3, chromosome 17 band p11.2, chromosome 18 bands q21.1 and q23, chromosome 22 bands q11.2 and q13.3, and chromosome X band p22. From these regions, most cases were reported on chromosomes 7, 15, and 22. The frequent occurrence of autistic patients with 15q11-q13 and 22q11.2 rearrangements may be partly due to the particular molecular organization of these chromosomal regions, as these rearrangements arise by unequal meiotic recombination between low copy repeat clusters. 60 The large number of cases with rearrangements of chromosome 15 is consistent with previous reports, and includes deletions, interstitial duplications, and isodicentric supernumerary marker chromosomes 15 leading to tetrasomy of the involved region. The latter, encompassing the Prader Willi/Angelman Syndrome critical region, are usually maternally inherited. The Prader Willi/Angelman critical region is gene rich and includes the gamma-aminobutyric acid receptor genes. These genes are expressed on neurons throughout the CNS, at both pre-and postsynaptic sites. Indeed, several association studies of the GABA receptor genes have produced significant results. [33] [34] [35] [36] Association studies of other potentially interesting genes for this region include ATP10C 61 and UBE3A.
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However, no linkage with LOD scores larger than 2.0 was found to this region.
The relatively large number of cases that was identified for chromosome 22 is somewhat remarkable. Most of these cases are deletions of the q11.2 and q13.3 region of chromosome 22. Cumulative evidence indicates that both deletions are associated with specific phenotypes, both of which include autistic features. 63, 64 Deletions of the terminal 22q13 distal band may represent a clinically definable syndrome that includes pervasive behaviors and impaired language development. 63 The 22q11.2 region is associated with the velo-cardial-facial Syndrome, with characteristic physical manifestations including typical facial appearance, anatomical and/or functional abnormalities of the palatal shelves such as cleft palate and velopharyngeal insufficiency, lymphoid tissue hypoplasia and conotruncal heart defects. [65] [66] [67] Although patients with this syndrome are considered to be at high risk to develop psychosis, 68, 69 the relationship between this syndrome and autism has only recently been recognized. 70 This may explain why no association studies for this region have been published so far. Comparable to the Prader Willi/ Angelman critical region on chromosome 15, no linkage was found for this region.
It could be speculated that the lack of linkage findings for 15q11-13 and 22q11.2 and 22q13.3 is caused by genetic heterogeneity of the autism phenotype or by the fact that genetic subtypes of autism are specific for the chromosome 15q and 22q rearrangement syndromes, respectively, and that a gene within these regions does not contribute significantly to autism in cytogenetically normal individuals.
For chromosome 7, the CROIs are located across the entire long arm of the chromosome. Chromosome 7 encompasses over 150 million nucleotides and 1917 gene structures. 71 A large collection of published and unpublished cases of autism with cytogenetic abnormalities of chromosome 7 is presented on the website of The Centre for Applied Genomics (www.chr7.org). Based on elaborate research regarding possible imprinted genes, fragile sites and duplications, candidate genes for several developmental disorders have been suggested, including candidate genes for autism. 71 Interestingly, for this chromosome there is a considerable overlap of the cytogenetic regions of interest and the results from linkage 25, 72 and association studies [38] [39] [40] 42, 73, 74 (see Figure 1 , Tables 1 and 2 ). Of special interest are the regions 7q21-q22 and 7q31-q32. Several candidate genes for autism are located within these regions, including PIK3CG (7q22), 37 74 and UBE2H (7q32). 75 Apart from the large number of case reports of chromosome 7, 15 and 22, interesting results were also found for chromosome 2 band q37, chromosome 5 band p14-p15, chromosome 11 band q25, chromosome 16 band q22.3, chromosome 17 band p11.2, chromosome 18 bands q21.1 and q23 and chromosome X band p22.
Additionally, some regions appear to strengthen results from linkage and association studies. For instance, overlap of several CROIs coincides with linkage/association findings at the same locus on 5p14, 76 10p14 76 and 16p13.3. 25 5p14 is a region of overlap with linkage findings, whereas 5p15 may represent a novel region. The estimated distance between both regions is 15 Mb. However, given the possibly rather low resolution of both linkage and cytogenetic findings, an alternative possibility of only one locus of interest at 5p14-15 indicated by both findings may also be valid. Important in this respect, the basepair coordinates of the CROIs refer to their most likely physical location. This, however, does not exclude a functional effect that reaches beyond the boundaries. Positional effects due to rearrangements up to 1.3 Mb away from the breakpoints have been reported. [77] [78] [79] New high-resolution methods of detection of copy number changes across the genome, such as array based comparative genomic hybridization (array-CGH), [80] [81] [82] representational oligonucleotide microarray analysis (ROMA) 83 and SNP-based arrays, 84 are increasingly applied in clinical and research studies. In the data collected for the current review, a small number of array-CGH findings is included, for instance, at 1p36.33 85 and at 6q21. 86 The increasing resolution of these methods improves accuracy of CROI delineation and will enable the detection of increasingly small copy number changes in patients with autism that would have remained undetected by the older methods.
It is important to note that segmental copy number changes in the human genome do not occur exclusively in patients, but appear to be present in unaffected subjects as well. 87, 88 Although the prevalence in the human population of such large-scale copy number polymorphisms (CNPs) is unknown, it is estimated that some of these CNPs occur up to 10% in the general population. It is possible that these genomic imbalances underlie certain human phenotypic variation and susceptibility to disease, for example, autism, and may partially explain the difficulties to identify candidate genes using linkage studies. For instance, Yu et al. 89 reported small deletions on chromosomes 7 and 8 in multiple families with two or more sibs with autism. While some of the detected deletions appeared to be specific for the affected families, others were found to be also prevalent in a control sample (and therefore not included in the present review). The increasing use of high-resolution methods for detection of segmental aneuploidies will provide essential information with regard to the prevalence of (small) regions with a gain or loss of copy number in the general population, and their potential significance for the autism phenotype.
One could question the value of studying CROIs associated with autism that lack support from linkage and/or association studies. In these regions, genes are likely to contribute to autism in the individuals with the cytogenetic abnormality, but appear to lack a significant effect at the population level. Indeed, if otherwise the function of such genes is not or only rarely affected (e.g. by a functional polymorphism), it is unlikely that these genes represent candidate genes for autism in the general population. However, whereas such genes may not be involved in autism in the general population, it is highly likely that they can provide essential information with regard to biological pathways and genetic networks involved in the causation of autism in the general population. This viewpoint demands a shift from a narrow focus on individual candidate genes towards a broader view involving the integration of available information into candidate gene networks or pathways. 90 This study has several limitations. First, despite the large number of cases that have been identified, cases may have been missed in the literature search. This may be due to the fact that some studies have a specific interest in either autism or cytogenetics, but not in both. For instance, a case may be presented with a well-described cytogenetic abnormality but without a detailed description of the behavioral phenotype. In addition, it is likely that many clinical cases have not been published, while at the same time a publication bias may exist in favor of the clinically most interesting cases.
A second limitation is caused by the fact that for some regions a broad availability of probes exists, in contrast to other regions. It is obvious that, if probes are widely available, the corresponding region will be detected more frequently. Thus, over-representation in the current overview may in some cases represent availability of probes instead of significant association with the autism phenotype. Inversely, other regions may be associated with autism but are under-represented in this review because of low availability of probes. In addition to the frequent de novo occurrence of aberrations, this may explain the finding of large numbers of cases for the 15q11-q13 region and the 22q11.2 and 22q13 regions. Nevertheless, this phenomenon only involves the chance of detection of a cytogenetic abnormality and does not affect the chance that abnormalities of such a region are related to autism. Therefore, it can still be concluded that these regions are of potential interest to autism. With the increasing use of molecular methods providing genome-wide information on copy number changes (e.g. array-CGH, ROMA, discussed above), this 'detection bias' is likely to disappear.
A third limitation of the present study is inherent to the fact that molecular data were not available in cases from the older literature, which potentially may have produced false interpretations of the genomic region of interest. This risk, however, seems limited because the assumption that a region is potentially interesting is based on the overlap of multiple cases, often independently detected in different research laboratories.
Fourth, we cannot exclude the possibility that genes with an important contribution to the pathogenesis of autism are located in regions of the genome for which cytogenetic abnormalities have not been reported so far. Although it cannot be ruled out that such a region exists, the large number of cases included in this review seems to decrease this possibility. Certainly, at present a potential relevance to autism of some of the less frequently or not reported regions in this overview cannot be excluded.
Fifth, our presentation of overlapping results from cytogenetic studies, linkage studies and exclusively those results from association studies that were reported as significant may lead to overinterpretations, since significant results from some association studies have been contradicted by other studies (e.g. the serotonin system 91,92 reelin 73, 93, 94 and the GABA receptor genes 95 ). However, irrespective of whether association findings agree on a certain locus, the value of the presented findings is the confirmation of a locus of interest through two different and independent approaches.
Despite these limitations, the present study offers several methodological advantages. First, to our knowledge, a complete list of relevant publications is provided. The inclusion of all relevant case reports that related cytogenetic abnormalities to the autism phenotype provides unbiased research data since no exclusion criteria (other than mosaicism) were used a priori.
Second, using the nearly completed DNA sequence of the human genome, 96 the sequence positions of all relevant cytogenetic regions were derived. This allows researchers in the field to easily combine our data with their own data regarding possible candidate genes or genomic regions.
Third, the clinical diagnosis of autism has been systematically evaluated. This permits a systematic ranking of CROIs based on the validity of the clinical diagnosis of autism.
The study of a specific phenotype, such as autism, in relationship to cytogenetic abnormalities is frequently met with skepticism. In the case of autism, this is often based on the assumption that many patients with cytogenetic abnormalities suffer from mental retardation and that in such cases autism cannot be diagnosed. It is therefore important to note that patients with mental retardation usually do not suffer from autism 97 and can be reliably distinguished from mentally retarded patients with autism. 98 Furthermore, mental retardation can be found in 70% of patients with autism and may be part of the phenotype. Indeed, in most of the identified cases of this literature study mental retardation was present.
In conclusion, the data presented in this review (1) confirm the association with autism of several genomic regions previously identified through linkage and or association studies, and (2) reveal possible novel, not previously identified genomic regions associated with autism. A next step for future research could be an integral analysis of available information on the genes residing in the CROIs to investigate whether specific biological pathways emerge from this combination. From a clinical perspective, it is imperative to include a cytogenetic evaluation of patients with an autism spectrum diagnosis, to which purpose the data provided by this review may be helpful.
